Comparing the current results to its competitors, Creative Medical Technology Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 21.93 %, recorded in the same quarter.
Creative Medical Technology Holdings Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment alongside pharmaceutical, biotechnology, and medical device firms, as well as other private and public stem cell companies focused on developing and commercializing cell-based medical technologies and therapies. Competitors often possess significantly greater financial, technological, research and development, marketing, and personnel resources. The company is unable to predict the timing or likelihood of competitors introducing products and therapies that may compete with its own. The field of regenerative medicine is advancing rapidly, particularly in the development of cell-based therapies and devices that isolate cells from human tissues such as bone marrow, adipose tissue, embryonic and fetal tissue, umbilical cord, peripheral blood, and skeletal muscle.
July 24, 2024
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an innovative biotechnology company specializing in regenerative therapies, has recently embarked on a groundbreaking initiative. The company announced the development of an AI-driven diagnostic and treatment program designed to aid patients exposed to biological and chemical weapons. By combining Artificial Intelligence (AI) with their proprietary human-induced pluripotent stem cells (iPSC), Creative Medical Technology aims to provide personalized and effective solutions for individuals facing the devastating consequences of exposure.Focus on Regenerative Medicine:Creative Medical Technology Holdings has cemented its position as a leading commercial...
March 6, 2024
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its innovative therapy, CELZ-101, also known as ImmCelzTM. This therapy is specifically developed to prevent allograft rejection in patients undergoing pancreatic islet transplantation.Creative Medical Technology Holdings, Inc. is a renowned leader in the field of regenerative medicine. The company focuses on developing novel therapies in various areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics. The successful receipt of the Orphan Drug Designation for CELZ-101 is a significant achievement and paves the way for potentia...
Publicly Traded Peers of Creative Medical Technology Holdings Inc
Iovance Biotherapeutics inc Share Performance
+267.09%
One Year
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.
Helius Medical Technologies Inc is a company that operates on a subscription-based business model, providing medical technology solutions for the treatment of neurological symptoms and conditions through its proprietary platform known as PoNS. This includes offering PoNS devices and related therapy services to healthcare providers and patients, with an aim to improve patient outcomes and quality of life.
Rigel Pharmaceuticals Inc is a biotechnology company that operates on a research and development business model. They focus on discovering, developing, and commercializing innovative small molecule drugs to address unmet medical needs. Their goal is to use their scientific expertise and strategic partnerships to bring new treatments to patients in various therapeutic areas.
Sources:
Creative Medical Technology Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Creative Medical Technology Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
